Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Transl Res. 2020 Oct 22;229:100–114. doi: 10.1016/j.trsl.2020.10.005

Figure 3. Mucolytic therapy enhances drug delivery to cancer cells and improves chemosensitivity.

Figure 3.

In a tranwell assay undiluted mucus, or mucus lysed with BRO (300 μg/ml) + NAC (250mM) in 10 ml PBS solution at 37°C for 2h, was coated onto the insert, OXAL (100μM) was added to the upper chamber for 24h, following which intracellular platinum in LS174T cells in the lower chamber was measured by AAS; insert is a pictorial representation of the transwell setup (A). Apoptotic cells following treatment in (A) were analyzed by phase-contrast microscopy (B). MCP tumor explants were treated with MMC (5 μM), BRO (20 μg/ml) + NAC (10 mM) or combination of MMC + BRO + NAC for 24h and apoptosis was measured by TUNEL assay (C). Confocal images were randomly taken and analyzed using Image J software to quantify the average intensity of TUNEL positivity (D). Error bars represent standard deviation (SD) from triplicate experiments (***P< .001).